Should I buy or sell Transphorm stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Transphorm in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGAN shares. View TGAN analyst ratings or view top-rated stocks .

What is Transphorm's stock price target for 2024?

2 equities research analysts have issued 1 year price objectives for Transphorm's shares. Their TGAN share price targets range from $3.50 to $8.00. On average, they expect the company's share price to reach $5.75 in the next twelve months. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for TGAN or view top-rated stocks among Wall Street analysts .

How have TGAN shares performed in 2023?

Transphorm's stock was trading at $2.61 at the beginning of 2023. Since then, TGAN shares have increased by 14.9% and is now trading at $3.00. View the best growth stocks for 2023 here .

When is Transphorm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our TGAN earnings forecast .

How were Transphorm's earnings last quarter?

Transphorm, Inc. (NASDAQ:TGAN) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $5.01 million for the quarter, compared to analyst estimates of $5.40 million. Transphorm had a negative net margin of 182.08% and a negative trailing twelve-month return on equity of 135.15%.

What other stocks do shareholders of Transphorm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Transphorm investors own include Adobe (ADBE) , American Battery Technology (ABML) , Capricor Therapeutics (CAPR) , Ciena (CIEN) , Editas Medicine (EDIT) , Eros STX Global (EROS) , Grayscale Ethereum Classic Trust (ETC) (ETCG) , Freeport-McMoRan (FCX) and Franco-Nevada (FNV) .

Who are Transphorm's major shareholders?

Transphorm's stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (7.46%), Ameriprise Financial Inc. (7.17%), Worth Venture Partners LLC (1.86%), Soros Fund Management LLC (0.55%), Charles Schwab Investment Management Inc. (0.14%) and Taylor Frigon Capital Management LLC (0.10%). View institutional ownership trends .

How do I buy shares of Transphorm?

Shares of TGAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Transphorm Stock Price, News & Analysis (NASDAQ:TGAN)

$3.00

+0.07 (+2.39%)

(As of 12/7/2023 ET)

Compare

Today's Range: $2.69
▼
$3.06
50-Day Range: $1.98
▼
$3.10
52-Week Range: $1.94
▼
$5.90

Volume: 82,502 shs
Average Volume: 49,420 shs
Market Capitalization: $185.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.75

Transphorm MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 91.7% Upside
$5.75 Price Target
Short Interest: Bearish
2.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$10,507 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.46) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.29 out of 5 stars

Computer And Technology Sector

555th out of 591 stocks

Semiconductors & Related Devices Industry

69th out of 72 stocks

3.3

Analyst's Opinion

Consensus Rating
Transphorm has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.75, Transphorm has a forecasted upside of 91.7% from its current price of $3.00.
Amount of Analyst Coverage
Transphorm has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
2.05% of the float of Transphorm has been sold short.
Short Interest Ratio / Days to Cover
Transphorm has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Transphorm has recently increased by 14.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Transphorm does not currently pay a dividend.
Dividend Growth
Transphorm does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TGAN.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Transphorm this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for TGAN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Transphorm insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,507.00 in company stock.
Percentage Held by Insiders
Only 2.47% of the stock of Transphorm is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Transphorm are expected to decrease in the coming year, from ($0.46) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Transphorm is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Transphorm is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Transphorm has a P/B Ratio of 9.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Transphorm Stock (NASDAQ:TGAN)

Transphorm, Inc., a semiconductor company, develops, manufactures, and sells gallium nitride (GaN) semiconductor components for high voltage power conversion applications in Mainland China, Hong Kong, Taiwan, the United States, Japan, South Korea, India, and Europe. The company's products include GaN field effect transistors in various packages. Its GaN devices allows customers to design power systems creating functional value in various end products, including smartphone power adapters/fast-chargers, power supplies for datacenter servers/communication, industrial power converters, chargers/converters/inverters for electric vehicles, and other applications. The company offers its products through regional distributors and sales representatives. Transphorm, Inc. was founded in 2007 and is headquartered in Goleta, California.

TGAN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TGAN Stock News Headlines

December 5, 2023 | americanbankingnews.com

Financial Contrast: Netlist (OTCMKTS:NLST) vs. Transphorm (NASDAQ:TGAN)

November 28, 2023 | americanbankingnews.com

Transphorm, Inc. (NASDAQ:TGAN) Director Kelly Smales Sells 3,995 Shares

See More Headlines

Receive TGAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Transphorm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/08/2023
Next Earnings (Estimated): 2/28/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Semiconductors & related devices
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: NASDAQ:TGAN
CUSIP: N/A
CIK: 1715768
Web: www.transphormusa.com
Phone: 805-456-1300
Fax: N/A
Employees: 129
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.75
High Stock Price Target: $8.00
Low Stock Price Target: $3.50
Potential Upside/Downside: +91.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,600,000.00
Net Margins: -182.08%
Pretax Margin: -182.08%
Return on Equity: -135.15%
Return on Assets: -78.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.63
Quick Ratio: 1.46

Sales & Book Value

Annual Sales: $18.58 million
Price / Sales: 10.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.33 per share
Price / Book: 9.09

Miscellaneous

Outstanding Shares: 61,960,000
Free Float: 60,430,000
Market Cap: $185.88 million
Optionable: Not Optionable
Beta: 0.54

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Primit A. Parikh Ph.D. (Age 51)
Co-Founder, President, CEO & Director
Comp: $390.66k
Mr. Cameron McAulay (Age 47)
Chief Financial Officer
Comp: $350.66k
Dr. Umesh K. Mishra Ph.D. (Age 65)
Chairman & CTO
Comp: $180k
Mr. Philip Zuk
Senior Vice President of Business Development & Marketing
Mr. Randy Berg
Human Resources Leader
Mr. Sal Barlett
Senior Vice President of Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TGAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Transphorm stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Transphorm in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGAN shares.
View TGAN analyst ratings or view top-rated stocks.
What is Transphorm's stock price target for 2024?: 2 equities research analysts have issued 1 year price objectives for Transphorm's shares. Their TGAN share price targets range from $3.50 to $8.00. On average, they expect the company's share price to reach $5.75 in the next twelve months. This suggests a possible upside of 91.7% from the stock's current price.
View analysts price targets for TGAN or view top-rated stocks among Wall Street analysts.
How have TGAN shares performed in 2023?: Transphorm's stock was trading at $2.61 at the beginning of 2023. Since then, TGAN shares have increased by 14.9% and is now trading at $3.00.
View the best growth stocks for 2023 here.
When is Transphorm's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our TGAN earnings forecast.

How were Transphorm's earnings last quarter?: Transphorm, Inc. (NASDAQ:TGAN) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $5.01 million for the quarter, compared to analyst estimates of $5.40 million. Transphorm had a negative net margin of 182.08% and a negative trailing twelve-month return on equity of 135.15%.
What other stocks do shareholders of Transphorm own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Transphorm investors own include Adobe (ADBE), American Battery Technology (ABML), Capricor Therapeutics (CAPR), Ciena (CIEN), Editas Medicine (EDIT), Eros STX Global (EROS), Grayscale Ethereum Classic Trust (ETC) (ETCG), Freeport-McMoRan (FCX) and Franco-Nevada (FNV).
Who are Transphorm's major shareholders?: Transphorm's stock is owned by many different institutional and retail investors. Top institutional shareholders include AIGH Capital Management LLC (7.46%), Ameriprise Financial Inc. (7.17%), Worth Venture Partners LLC (1.86%), Soros Fund Management LLC (0.55%), Charles Schwab Investment Management Inc. (0.14%) and Taylor Frigon Capital Management LLC (0.10%).
View institutional ownership trends.
How do I buy shares of Transphorm?: Shares of TGAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:TGAN) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial